GlassScriptPhysician profile
Joseph Tripodi
NPI 1386628964
$955.78
in general payments reported to CMS, 2019-2025
10 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $49.41 · 2023: $198 · 2024: $418 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Education: $13.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.53 |
| Education | $13.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.83 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceuticals, INC. | $167.33 | 2021 | |
| Amgen INC. | $66.25 | 2023-2024 | Otezla, Repatha |
| Novo Nordisk INC | $62.29 | 2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $56.60 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.41 | 2022 | |
| Qol Medical, LLC | $35.80 | 2024 | Sucraid |
| Abbvie INC. | $31.41 | 2023-2024 | Vraylar |
| Glaxosmithkline, LLC. | $27.22 | 2024 | Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $13.64 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Tripodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.